Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Merger or Acquisition (June 2025)
8 slides from Royalty Pharma's merger presentation, June 2025
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: Daraxonrasib royalty acquisition
Daraxonrasib royalty acquisition June 2025
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: Daraxonrasib a potential practice-changing medicine for cancer
Daraxonrasib a potential practice-changing medicine for cancer 1 2 3 Daraxonrasib is in Phase 3 Impressive clinical results Multi-blockbuster for pancreatic & lung cancer and favorable safety commercial opportunity Revolution Medicines’ daraxonrasib, a RAS(ON) Large Phase 1 study demonstrated effica
Slide 5: RP provides up to $2 billion of flexible and scaled funding
RP provides up to $2 billion of flexible and scaled funding Daraxonrasib consensus sales projections (Unadjusted sales; $ in millions) • Up to $1.25bn ($250m upfront) for synthetic royalty on daraxonrasib(1) ▪ Tranched structure limits risk as additional funding available on positive $7,311 $6,806 P
Slide 6: Initial clinical results demonstrate impressive efficacy
Initial clinical results demonstrate impressive efficacy Large Phase 1 trial enrolled over 400 patients Daraxonrasib clinical results to date 2L pancreatic cancer cohort(1,3) 2L lung cancer cohort(2,3) (PDAC) (NSCLC) 17.7 14.5 11.3-11.8(5) 9.8 8.5 6.1-6.9(4) 3.7-4.5(5) 2.0-3.5(4) Progression free su
Slide 7: Royalty Pharma sees multi-blockbuster potential for daraxonrasib
Royalty Pharma sees multi-blockbuster potential for daraxonrasib Revolution Medicines would likely launch with a significant first to market advantage in a space where the unmet need is profound Pancreatic cancer(1,2) Non-small cell lung cancer(2) Strengthens Zoldonrasib(3), other RAS- ~56,000 new U
Slide 8: Daraxonrasib royalty and debt facility terms
Daraxonrasib royalty and debt facility terms Royalty terms Tranche 1 Tranche 2 Tranche 3(1) Tranche 4(1) Tranche 5(1) Total Amount $250m $250m Up to $250m Up to $250m Up to $250m $1.25bn Positive data FDA approval in 2L Sales milestone Positive Phase 3 data in Timing Immediate (RASolute 302) pancrea